The clinical usefulness of glucated haemoglobin in diabetes care evaluated by use of a medical technology assessment strategy

Danish Medical Bulletin

Volumn 44, Issue 3, 1997, Pages 303-315

  Larsen, Mogens Lytken ^a,b  

^a ODENSE UNIVERSITY HOSPITAL   (Denmark)

^b NONE   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

GLYCOSYLATED HEMOGLOBIN;

BIOMEDICAL TECHNOLOGY ASSESSMENT; COST BENEFIT ANALYSIS; DIABETES MELLITUS; DIAGNOSTIC VALUE; GLUCOSE BLOOD LEVEL; HEMOGLOBIN DETERMINATION; HUMAN; HUMAN CELL; HUMAN TISSUE; NON INSULIN DEPENDENT DIABETES MELLITUS; REVIEW; TREATMENT PLANNING;

ADULT; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; EVALUATION STUDIES; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; MALE; TECHNOLOGY ASSESSMENT, BIOMEDICAL; TECHNOLOGY, MEDICAL;

EID: 0030844611     PISSN: 09078916     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (174)

1. Larsen ML. Evaluation of a new capillary blood collection system for laboratory assay of glycated haemoglobin. Scand J Clin Lab Invest 1986; 46: 315-7.
2. Larsen ML. The utility of glycated hemoglobin in identification of impaired glucose tolerance. Diabetes Research 1989; 12: 67-70.
3. Larsen ML, Hørder M. Metabolic evaluation of non-insulin-dependent diabetes in primary health care - the clinical usefulness of glycated haemoglobin measurements. Scand J Prim Health Care 1989; 7: 167-71.
4. Larsen ML, Petersen PH, Horder M, Mogensen EF. Discrepancies in assessment of metabolic regulation in insulin-dependent diabetes mellitus - can we do without measurements of glycated haemoglobin? Diabetes Research 1990; 14: 75-8.
5. Larsen ML, Hørder M, Mogensen EF. Effect of long-term monitoring of glycosylated hemoglobin levels in insulin-dependent diabetes mellitus. N Eng J Med 1990; 323: 1021-5.
6. Larsen ML, Blaabjerg O, Petersen PH, Hansen H, Hørder M. Analytical goal setting prior to selection of a method for glycated haemoglobin. Scand J Clin Lab Invest 1990; 50: 715-21.
7. 1C assays derived using different strategies. Ann Clin Biochem 1991; 28: 272-8.
8. Goldstein DE. Is glycosylated hemoglobin clinically useful? N Eng J Med 1984; 310: 384-5.
9. Baynes JW, Bunn HF, Goldstein DE, Harris M, Martin DB, Peterson C, Winterhalter K. National Diabetes Data Group: Report of the expert committee on glycosylated hemoglobin. Diabetes Care 1984; 7: 602-6.
10. American College of Physicians, Health and Public Policy Committee. Glycosylated hemoglobin assays in the management and diagnosis of diabetes mellitus. Ann Int Med 1984; 101: 710-3.
11. Mayer TK, Freedman ZR. Protein glycosylation in diabetes mellitus: a review of laboratory measurements and of their clinical utility. Clin Chim Acta 1983; 127: 147-84.
12. Rock RC. Technology assessment in laboratory: rationalizing or rationing? Clinics in Laboratory Medicine 1981; 1: 3-19.
13. Office of Technology Assessment, United States Congress. Strategies for medical technology assessment. Washington DC: U.S. Goverment Printing Office, 1982.
14. Fineberg HV, Hiatt HH. Evaluation of medical practices. The case for technology assessment. N Eng J Med 1979; 301: 1086.
15. Jonsson E, Reiser SJ. Editors' introduction. Int J Technol Assessm Hlth Care 1985; 1: 1-2.
16. Brorsson B, Wall S. Assessment of medical technology - problems and methods. Swedish Medical Research Council, Sweden 1985.
17. Riis P. Medical technology assessment - for whom tolls the term. Acta Med Scand 1985; 218: 433-4.
18. Service FJ, O'Brien PC, Rizza RA. Measurements of glucose control. Diabetes Care 1987; 10: 225-37.
19. Krall LP. Importance of "control" and how to achieve it! In L.P. Krall (ed.), World Book of Diabetes in Practice, Vol. 2. Amsterdam-New York-Oxford, Elsevier 1986: 50-3.
20. Singer DE, Coley CM, Samet JH, Nathan DM. Tests of glycemia in diabetes mellitus. Ann Intern Med 1989; 110: 125-37.
21. Malone JI, Rosenbloom AL, Grgic A, Weber FT. The role of urine sugar in diabetic management. Am J Dis Child 1976; 130: 1324-7.
22. Hayford JT, Weydert JA, Thompson RG. Validity of urine glucose measurements for estimating plasma glucose concentration. Diabetes Care 1983; 6: 40-4.
23. Johansen K, Svendsen PA, Lørup B. Variations in renal threshold for glucose in type 1(insulin-dependent) diabetes mellitus. Diabetologia 1984; 26: 180-2.
24. Fraser CG. Analytical goals for glucose analyses. Ann Clin Biochem 1986; 23: 379-89.
25. Burrin JM, Alberti KGMM. What is blood glucose: Can it be measured? Diabetic Med 1990; 7: 199-206.
26. Consensus Development Panel. Consensus statement on self-monitoring of blood glucose. Diabetes Care 1987; 10: 95-9.
27. Schlichtkrull J, Munck O, Jersild M. The M-value, an index of blood-sugar control in diabetics. Acta Med Scand 1965; 177: 95-102.
28. Service FJ, Molnar GD, Rosevear JW, Ackerman EA, Gatewood LC, Tayleor WF. Mean amplitude of glycemic excursions, a measure of diabetic instability. Diabetes 1970; 19: 644-55.
29. McFarland KF, Catalano EW, Day JF, Thorpe SR, Baynes JW. Nonenzymatic glucosylation of serum proteins in diabetes mellitus. Diabetes 1979; 28: 1011-14.
30. Bunn HF. Nonenzymatic glycosylation of protein: Relevance to diabetes. Am J Med 1981; 70: 325-30.
31. Bunn HF, Gabbay KH, Gallop PM. The glycosylation of hemoglobin: Relevance to diabetes mellitus. Science 1978; 200: 21-7.
32. Day JF, Thorpe SR, Baynes JW. Nonenzymatically glucosylated albumin. J Biol Chem 1979; 254: 595-7.
33. Robins SP, Bailey AJ. Age-related changes in collagen: The identification of reducible lysine-carbohydrate condensation products. Biochem Biophys Res Commun 1972; 48: 76-84.
34. Bailey AJ, Robins SP, Tanner JA. Reducible components in the proteins of human erythrocyte membrane. Biochim Biophys Acta 1976; 434: 51-7.
35. Stevens VJ, Rouzer CA, Monnier VM, Cerami A. Diabetic cataract formation: Potential role of glycosylation of lens crystallins. Proc Natl Acad Sci 1978; 75: 2918-22.
36. Kennedy L, Baynes JW. Non-enzymatic glycosylation and the chronic complications of diabetes: an overview. Diabetologia 1984; 26: 93-8.
37. Rahbar S. An abnormal hemoglobin in red cells of diabetics. Clin Chem Acta 1968; 22: 296-8.
38. Rahbar S, Blumenfeld O, Ranney HM. Studies of an unusual hemoglobin in patients with diabetes mellitus. Biochem Biophys Res Commun 1969; 36: 838-43.
39. 1c. Biochem Biophys Res Commun 1975; 67: 103-9.
40. 1c. J Clin Invest 1976; 57: 1652-9.
41. Garlick RL, Mazer JS, Higgins PJ, Bunn HF. Characterization of glycosylated hemoglobins. J Clin Invest 1983; 71: 1062-72.
42. 1c as an indicator of the degree of glucose intolerance in diabetes. Diabetes 1976; 25: 230-2.
43. 1c in diabetes mellitus. N Eng J Med 1976; 295: 417-20.
44. Gonen B, Rubenstein AH, Rochman H, Tanega SP, Horwitz DL. Hæmoglobin A1: an indicator of the metabolic control of diabetic patients. Lancet 1977; 2: 734-6.
45. Gabbay KH, Hasty K, Breslow JL, Ellison RC, Bunn HF, Gallop PM. Glycosylated hemoglobins and long-term blood glucose control in diabetes mellitus. J Clin Endocrinol Metab 1977; 44: 859-64.
46. 1c concentrations after initial insulin treatment for newly discovered diabetes. Br Med J 1978; 1: 741-2.
47. Gonen B, Rubenstein AH. Haemoglobin A1 and diabetes mellitus. Diabetologia 1978; 15: 1-8.
48. Boden G, Master RW, Gordon SS, Shuman CR, Owen OE. Monitoring metabolic control in diabetic outpatients with glycosylated hemoglobin. Ann Intern Med 1980; 92: 357-60.
49. Svendsen PA, Lauritzen T, Søegaard U, Nerup J. Glycosylated haemoglobin and steady-state mean blood glucose concentration in type 1 (insulin-dependent) diabetes. Diabetologia 1982; 23: 403-5.
50. Goldstein DE, Wiedmeyer H-M, England JD, Little RR, Parker KM. Recent advances in glycosylated hemoglobin measurements. CRC Critical Reviews, Clinical Laboratory Sciences 1984; 21: 187-228.
51. Nomenclature announcement. Nomenclature Committee of IUB(NC-IUB) and IUB-IUPAC Joint Commission on Biochemical Nomenclature (JCBN). Arch Biochem Biophys 1984, 229: 399-401.
52. Westgard JO, Groth T, de Verdier C-H. Principles for developing improved quality control procedures. Scand J Clin Lab Invest 1984; 44(suppl.172): 19-41.
53. Gonen B, Rochman H, Rubenstein AH. Metabolic control in diabetes patients: assessment by hemoglobin A1 values. Metabolism 1979 (Suppl.1); 448-52.
54. Wålinder O, Wibell L, Boström H. The clinical value of HbA1-determinations. Acta Med Scand 1980 (suppl.639): 17-22.
55. 1c levels on repetitive determination in diabetic out-patients. J Clin Endocrin Metab 1981; 52: 1019-22.
56. Goldstein DE, Parker KM, England JD, England JD jr., Wiedmeyer H-M, Rawlings SS, Hess R, Little RR, Simonds JF, Breyfogle RP. Clinical application of glycosylated hemoglobin measurements. Diabetes 1982; 31 (suppl.3): 70-8.
57. Petersen PH, Larsen ML, Hørder M. Prerequisites for the maintenance of a certain state of health by biochemical monitoring. In: Harris EK, Yasaka T, eds. Maintaining a healthy state within the individual. Amsterdam: Elsevier 1987: 137-45.
58. Fraser CG. Desirable performance standards for clinical chemistry tests. Adv Clin Chem 1983; 23: 299-339.
59. 1c. Diabetes 1980; 29: 623-8.
60. 1c induced by short-term changes in glucose concentration. Diabetologia 1980; 19: 130-6.
61. Eberentz-Lhomme C, Ducrocq R, Intrator S, Elion J, Nunez E, Assan R. Haemoglobinopathies: a pitfall in the assessment of glycosylated haemoglobin by ion-exchange chromatography. Diabetologia 1984; 27: 596-8.
62. Harris EK. Statistical principles underlying analytical goal-setting in clinical chemistry. Am J Clin Pathol 1979; 72: 374-82.
63. Fraser CG. The application of theoretical goals based on biological variation data in proficiency testing. Arch Pathol Lab Med 1988; 112: 404-15.
64. Fraser CG, Petersen PH, Larsen ML. Setting analytical goals for random analytical error in specific clinical monitoring situations. Clin Chem 1990; 36: 1625-8.
65. Boucher BJ, Burrin JW, Gould BJ, John PN, Lewis G, Owens C, Paisey R, Pennock CA, Poon PYW, Ross IS, Welch SG, White JM. A collaborative study of the measurement of glycosylated haemoglobin by several methods in seven laboratories in the United Kingdom. Diabetologia 1983; 24: 265-71.
66. Mortensen HB, Nielsen L, Søegaard U, Svendsen PA, Nerup J. Comparison of six assays for glycosylated haemoglobin determination. Scand J Clin Lab Invest 1983; 43: 357-62.
67. Peterson CM, Jovanovic L, Raskin P, Goldstein DE. A comparative evaluation of glycosylated haemoglobin assays: feasibility of references and standards. Diabetologia 1984; 26: 214-7.
68. 1c in diabetic patients by use of electrofocusing. In: Radola BJ, ed. Electrophoresis 1979. New York, NY: De Gruyter 1980: 655-61.
69. 1c by thin-layer isoelectric focusing. J Chromatogr 1980; 182: 325-33.
70. 1c by isoelectric focusing. Clin Chem 1982; 28: 9-12.
71. Mortensen HB, Marshall MO. Effect of saline incubation on red cell content of glucosylated haemoglobins studied by iso-electric focusing. Clin Chem Acta 1983; 132: 213-7.
72. Bliss CI. Statistics in biology. New York: McGraw-Hill 1967.
73. Solberg HE. Approved recommendations (1987) on the theory of reference values. Part 5. Statistical treatment of collected reference values: determinations of reference limits. J Clin Chem Biochem 1987; 25: 645-56.
74. World Health Organization. Diabetes Mellitus. Report of a study group. (WHO Technical Report Series No 727), WHO, Genova 1985.
75. Keen H. Diagnosis and classification of diabetes mellitus. In: World Book of Diabetes in Practice. Vol 2. Krall LP, ed. Elsevier, Amsterdam 1986: 8-15.
76. Dods RF, Bolmey C. Glycosylated hemoglobin assay and oral glucose tolerance test compared for detection of diabetes mellitus. Clin Chem 1979; 25: 764-8.
77. 1c and the diagnosis of diabetes mellitus. Acta Med scand 1981; 210: 313-6.
78. Kesson CM, Young RE, Talwar D, Whitelaw JW, Robb DA. Glycosylated hemoglobin in the diagnosis of non-insulin dependent diabetes mellitus. Diabetes Care 1982; 5: 395-8.
79. Hall PM, Cook JG, Sheldon J, Rutherford SM, Gould BJ. Glycosylated hemoglobins and glycosylated plasma proteins in the diagnosis of diabetes mellitus and impaired glucose tolerance. Diabetes Care 1984; 7: 147-50.
80. Cederholm J, Ronquist G, Wibell L. Comparison of glycosylated haemoglobin and the oral tolerance test. Diab Metab 1984; 10: 224-9.
81. Albutt EC, Nattrass M, Northam BE. Glucose tolerance test and glycosylated hemoglobin measurements for diagnosis of diabetes mellitus -an assessment of the criteria of the WHO Expert Committee on Diabetes Mellitus 1980. Ann Clin Biochem 1985; 22: 67-73.
82. Lester E, Frazer AD, Sheppers CA, Woodroffe FJ. Glycosylated haemoglobin as an alternative to the glucose tolerance test for the diagnosis of diabetes mellitus. Ann Clin Biochem 1985; 22: 74-8.
83. John WG, Richardson RW. Glycosylated haemoglobin levels in patients referred for oral glucose tolerance tests. Diab Med 1986; 3: 46-8.
84. 1c by a new liquid-chromatographic assay: Methodology, clinical utility, and relation to glucose tolerance evaluated. Clin Chem 1986; 32: 1867-72.
85. Little RR, England JD, Wiedmeyer H-M, England JD, McKenzie EM, Pettitt DJ, Knowler WC, Goldstein DE. Relationship of glycosylated hemoglobin to oral glucose tolerance. Diabetes 1988; 37: 60-4.
86. Wiener K. Diagnosisi of diabetes melltus: pitfalls in the glucose tolerance test. Br Med J 1987; 295: 1363.
87. Goldstein DE, Little RR, Wiedmeyer H-M, England JD, McKenzie EM. Glycated hemoglobin: methodologies and clinical applications. Clin Chem 1986; 32: B64-70.
88. Clarke BF. The effect of sulfonylurea on glycosylated hemoglobin. In: The role of sulfonylureas in the treatment of insulin-dependent diabetics. New York, Science and Medicine 1980; 18-23.
89. Wålinder O, Wibell L, Tuvemo T. Relation between hemoglobin A1 and determinations of glucose in diabetics treated with and without insulin. Diabete Metab 1980; 6: 251-5.
90. Jovanovic L, Peterson CM. The clinical utility of glycosylated hemoglobin. Am J Med 1981; 70: 331-8.
91. Gries FA, Alberti KGMM. Management of non-insulin-dependent diabetes mellitus in Europe: a consensus statement. IDF bull 1987; 32: 169-74.
92. Alberti KGMM, Gries FA. Management of non-insulin-dependent diabetes mellitus in Europe: a concensus view. Diabetic Med 1989; 7: 167-71.
93. 1c with basal insulin supplement, sulphonylurea or biguanide therapy in maturity-onset diabetes. Diabetes 1985; 34: 793-8.
94. Lenzi S, Giampietro O, Giovanitti G, Sampietro T, Miccoll R, Navalesi R. The clinical usefulness of glycated hemoglobin in monitoring diabetes mellitus: A long-term study. Clin Chem 1987; 33: 55-6.
95. Kaplan LA, Cline D, Gartside P, Burstein S, Sperling M, Stein EA. Hemoglobin A1 in hemolysates from healthy and insulin-dependent diabetic children, as determined with a temperature-controlled mini-column assay. Clin Chem 1982; 28: 13-8.
96. Nathan DM, Singer DE, Hurxthal K, Goodson JD. The clinical information value of the glycosylated hemoglobin assay. N Eng J Med 1984; 310: 341-6.
97. Bacon GE, Ladu C, Shein HE, Rucknagel DL. Evaluation of glycosylated hemoglobin in the management of young patients with insulin-dependent diabetes mellitus. J Adoles Health Care 1986; 7: 187-90.
98. Assal JP, Mühlhauser I, Pernet A, Gfeller R, Jörgens V, Berger M. Patient education as the basis for diabetes care in clinical practice and research. Diabetologia 1985; 28: 602-13.
99. Goldstein DE, Valluck J, Hazelwood LF. The test that never forgets. Diabetes Forecast 1985; Jan-Feb: 35-6.
100. Johnson SB. Psychological aspects of childhood diabetes. J Child Psychol Psychiat 1988; 29: 729-38.
101. Lockington SB, Farrant S, Meadows KA, Dowlatshahi D, Wise PH. Knowledge profile and control in diabetic patients. Diabetic Med 1988; 5: 381-6.
102. Lockington SB, Powles S, Meadows KA, Wise PH. Attitudes, knowledge and blood glucose control. Diabetic Med 1989; 6: 309-13.
103. Stone DH. Design a questionnaire. BMJ 1993; 307: 1264-6.
104. 1c as a step forward? Diabetes 1991; 40(suppl.1): 1613(abstract).
105. Mogensen CE. Management of diabetic renal involvement and disease. Lancet 1988; i: 867-70.
106. Home P. Glycosylated haemoglobin revisited. Diabetic Med 1990; 7: 385-6.
107. Drummond MF, Stoddart GL, Torrance GW. Methods for the economic evaluation of health care programmes. Oxford University Press, Oxford 1987.
108. Winocour PH, Bhatnagar D, Reed P, Dhar H. Does the measurement of serum fructosamine accurately reflect levels of glycated albumin in insulin-dependent diabetes? Ann Clin Biochem 1987; 24: 47-52.
109. 1c. Clin Chim Acta 1988; 175: 135-42.
110. Winocour PH, Bhatnagar D, Kalsi P, Hillier VF, Anderson DC. Relative clinical usefulness of glycosylated serum albumin and fructosamine during short-term changes in glycemic control in IDDM. Diabetes Care 1989; 12: 665-72.
111. Fisken RA, Chan AW, Hanlon A, MacFarlane IA. Longitudinal changes in serum fructosamine do not parallel those in glycated haemoglobin in young adults with insulin-dependent diabetes. Clin Chem Acta 1990; 191: 79-86.
112. Watts GF, Macleod AF, Benn JJ, Slavin BM, Morris RW, Williams CD, Kearney EM, Lowy C, Sönksen PH. Comparison of the real-time use of glycosylated haemoglobin and plasma fructosamine in the diabetic clinic. Diabetic Med 1991; 8: 573-9.
113. Koskinen P, Erkkola R, Viikari J, Mattila K, Irjala K. Blood glycated haemoglobin, serum fructosamine, serum glycated albumin and serum glycated total protein as measures of glycaemia in diabetes mellitus. Scand J Clin Lab Invest 1992; 52: 863-9.
114. Klein BEK, Moss SE, Klein R. Longitudinal measure of glycemic control and diabetic retinopathy. Diabetes Care 1987; 10: 273-7.
115. Klein R, Klein BEK, Moss SE, Davis MD, DeMets DL. Glycosylated hemoglobin predicts the incidence and progression of diabetic retinopathy. JAMA 1988; 260: 2864-71.
116. McCance DR, Hadden DR. Atkinsson AB, Archer DB, Kennedy L. Long term glycemic control and diabetic retinopathy. Lancet 1989; ii: 824-8.
117. Chase HP, Jackson WE, Hoops SL, Crockerham RS, Archer PG, O'Brien D. Glucose control and the renal and retinal complications of insulin-dependent diabetes. JAMA 1989; 261: 1155-60.
118. Hollman RR, Dornan TL, Mayon-White V et al. Prevention of detoriation of renal and sensory-nerve function by more intensive management of insulin-dependent diabetic patients. Lancet 1983; i: 204-8.
119. Kroc Collaborative Study Group. Blood glucose control and the evolution of diabetic retinopathy and albuminuria. N Eng J Med 1985; 311: 364-72.
120. Lauritzen T, Frost-Larsen K, Larsen HW, Deckert T, Steno Study Group. Two-year experience with continuous subcutaneous insulin infusion in relation to retinopathy and neuropathy. Diabetes 1985;34(suppl.3): 74-9.
121. Dahl-Jørgensen K, Brinchmann-Hansen O, Hanssen KF, Ganes T, Kierulf P, Smeland E, Sandvik L, Aagenaes Ø. Effect of near-normoglycemia for two years on progression of early diabetic retinopathy, nephropathy and neuropathy: the Oslo Study. Br Med J 1986; 293: 1195-9.
122. Beck-Nielsen H, Richelsen B, Mogensen CE, Olsen T, Ehlers N, Nielsen CB, Charles P. Effect of insulin pump treatment for 1 year on renal function and retinal morphology in patients with IDDM. Diabetes 1985; 8: 585-9.
123. Feldt-Rasmussen B, Mathiesen ER, Deckert T. Effect of two years of strict metabolic control on the progression of incipient nephropathy in insulin-dependent diabetes. Lancet 1986; ii: 1300-4.
124. Nyberg G, Blohme G, Nordén G. Impact of metabolic control in progression of clinical diabetic nephropathy. Diabetologia 1987; 30: 82-6.
125. Marcus SH, Grover PL, Revicki DA. The method of information synthesis and its use in the assessment of health care technology. J of Technology Assessment in Health Care 1987; 3: 497-508.
126. College of American Pathologists. Electrophoresis-chromatography survey 1985 set EC-D. Northfield, IL: College of American Pathologists, 1985: 5.
127. John WG. Glycated haemoglobin analyses - assessment of within- and between-laboratory performance in a large UK region. Ann Clin Biochem 1987; 24: 453-60.
128. Little RR, Wiedmeyer H-M, England JD, Naito HK, Goldstein DE. Interlaboratory comparison of glycohemoglobin results: College of American Pathologists Survey Data. Clin Chem 1991; 37: 1725-9.
129. John WG, Bullock DG, MacKenzie F. Methods for the analysis of glycated haemoglobins: What is being measured? Diabetic Med 1992; 9: 15-9.
130. 1c measurements performed at different local laboratories and a selected central reference laboratory. Upsala J Med Sci 1993; 98: 275-82.
131. Weykamp CW, Penders TJ, Muskiet FAJ, Slik Wvd. Glycohaemoglobin: comparison of 12 analytical methods, applied to lyophilized haemolysates by 101 laboratories in an external quality assurance programme. Ann Clin Biochem 1993; 30: 169-74.
132. Weykamp CW, Penders TJ, Muskiet FAJ, Slik Wvd. Effect of calibration on dispersion of glycohemoglobin values determined by 111 laboratories using 21 methods. Clin Chem 1994; 40: 138-44.
133. Allen KR, Hamilton AD, Bodansky HJ, Poon P. Prevalence of haemoglobin variants in a diabetic population and their effect on the glycated haemoglobin measurements. Ann Clin Biochem 1992; 29: 426-429.
134. Kilpatrick ES, Small M, Rumley A, Dominiczak MH. Increased fetal hemoglobin in insulin-treated diabetes mellitus contributes to the imprecision of glycohemoglobin measurements, Clin Chem 1993; 39: 833-5.
135. Kilpatrick ES, Rumley AG, Dominiczak MH, Small M. Glycated haemoglobin values: problems in assessing blood glucose control in diabetes mellitus. BMJ 1994; 309: 983-6.
136. Weykamp CW, Penders TJ, Siebelder CWM, Muskiet FAJ, Slik Wvd. Interference of carbamylated hemoglobins in assays of glycohemoglobin by HPLC, electrophoresis, affinity chromatography, and enzyme immunoassay. Clin Chem 1993; 39: 138-42.
137. Weykamp CW, Penders TJ, Muskiet FAJ, Slik Wvd. Influence of hemoglobin variants and derivatives on glycohemoglobin determinations, as investigated by 102 laboratories using 16 methods. Clin Chem 1993; 39: 1717-23.
138. Fraser CG. The necessity of achieving good laboratory performance. Diabetic Medicine 1990; 7: 490-3.
139. Phillipou G, Phillips PJ. Intraindividual variation of glycohemoglobin: Implications for interpretation and analytical goals. Clin Chem 1993; 39: 2305-8.
140. The DCCT Research Group. Feasibility of centralized measurements of glycated hemoglobin in the diabetes control and complications trial: A multi center study. Clin Chem 1987; 33: 2267-71.
141. American Diabetes Association. Office guide to diagnosis and classification of diabetes mellitus and other categories of glucose intolerance. Diabetes Care 1993; 16(suppl.2): 4.
142. Little RR, England JD, Wiedmeyer HM, Madsen RW, Pettitt DJ, Knowler WC, Goldstein DE. Glycated haemoglobin predicts progression to diabetes mellitus in Pima Indians with impaired glucose tolerance. Diabetologia 1994; 37: 252-6.
143. Stern MP, Rosenthal M, Haffner SM. A new concept of impaired glucose tolerance. Arteriosclerosis 1985; 5: 311-4.
144. McCance DR, Hanson RL, Charles M-A, Jacobsson LTH, Pettitt DJ, Bennett PH, Knowler WC. Comparison of tests for glycated haemoglobin and fasting and two hour plasma glucose concentrations as diagnostic methods for diabetes. BMJ 1994; 308: 1323-8.
145. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Eng J Med 1993; 329: 977-86.
146. Lasker RD. The diabetes control and complications trial. Implications, for policy and practice.
147. Dahl-Jørgensen K, Brinchmann-Hansen O, Bangstad H-J. Hanssen KF. Blood glucose control and microvascular complications - what do we do now? Diabetologia 1994; 37: 1195-9.
148. European IDDM Policy Group 1993. Consensus guidelines for the management of insulin-dependent (type 1) diabetes. Diabetic Med 1993; 10: 990-1005.
149. Brownlee M. Glycation products and the pathogenesis of diabetes complications. Diabetes Care 1992; 15: 1835-43.
150. Greene DA, Sima AAF, Stevens MJ, Feldman EL, Lattimer SA. Complications: neuropathy, pathogenetic considerations. Diabetes Care 1992; 15: 1902-25.
151. U.K. Prospective Diabetes Study. VIII. Study design, progress and performance. Diabetologia 1991; 34: 877-90.
152. Agardh C, Scherstén B. Diabetic control in community care. Scand J Prim Health Care 1985; 3: 15-8.
153. Bradshaw C, Eccles MP, Choi HY. Can general practitioners assess diabetic control? Can anybody do any better? Diabetic Med 1991; 8: 543-6.
154. Abraira C, Emanuele N, Colwell J, Henderson W, Comstock J, Levin S, Nuttall F, Sawin C. Glycemic control and complications in type II diabetes. Diabetes Care 1992; 11: 1560-9.
155. Alberti KGMM, Gries FA, Jervell J, Krans HMJ. A desktop guide for the management of non-insulin-dependent diabetes mellitus (NIDDM): an update. Diabetic Med 1994; 11: 899-909.
156. Butler C, Peters J, Stott N. Glycated haemoglobin and metabolic control of diabetes mellitus: external versus locally established clinical targets for primary care. BMJ 1995; 310: 784-8.
157. Surawy C. Knowledge about diabetes in type 1 patients is related to metabolic control. Diabetic Med 1989; 6: 784-6.
158. Bloomgarden ZT, Karmally W, Metzger J, Brothers M, Nechemias C, Bookman J, Faierman D, Ginsberg-Fellner F, Rayfield E, Brown Wv. Randomized, controlled trial of diabetic patient education: Improved knowledge without improved metabolic status. Diabetes Care 1987; 10: 263-72.
159. Rubin RR, Peyrot M, Saudek CD. Effect of diabetes education on self-care, metabolic control, and emotional well-being. Diabetes Care 1989; 12: 673-9.
160. Mühlhauser I, Berger M. Diabetes education and insulin therapy: when will they ever learn? J Int Med 1993; 233: 321-6.
161. Tuttleman M, Lipsett L, Harris MI. Attitudes and behaviors of primary care physicians regarding tight control of blood glucose in IDDM patients. Diabetes Care 1993; 16: 765-72.
162. Little RR, Wiedmayer H-M, England JD, Knowler WC, Goldstein DE. Measurements of glycosylated whole-blood protein for assessing glucose control in diabetes: Collection and storage of capillary blood on filter paper. Clin Chem 1985; 30: 213-6.
163. 1c monitoring. Diabetic Med 1991; 8: 784-7.
164. 1c specimens. Diabetes Care 1992; 15: 700-1.
165. Gay EC, Cruickshanks KJ, Chase HP, Klingensmith G, Hamman RF. Accuracy of a filter paper method for measuring glycosylated hemoglobin. Diabetes Care 1992; 15: 108-10.
166. Rumley AG, Carlton G, Small M. Within-clinic glycosylated haemoglobin measurement. Diabetic Med 1990; 7: 838-40.
167. 1c. Diabetic Med 1992; 10: 260-3.
168. Pickup JC, Crook MA, Tutt P. Blood glucose and glycated haemoglobin measurements in hospital: which method? Diabetic Med 1993; 10: 402-11.
169. Olivera EM, Duhalde EP, Gagliardino JJ. Costs of temporary and permanent disability induced by diabetes. Diabetic Med 1991; 14: 593-6.
170. Bransome ED. Financing the care of diabetes mellitus in the U.S. Diabetes Care 1992; 15(suppl.1): 1-5.
171. Gagliardino JJ, Olivera EM, Barragán H, Puppo RA. A simple economic evaluation model for selecting diabetes health care strategies. Diabetic Med 1992; 10: 351-4.
172. Olivarius NF, Lauritzen T, Beck-Nielsen H, Fog J, Mogensen CE. Co-ordination of diabetes care in the primary and secundary health care system in Denmark. Diabetic Med 1994; 11: 123-5.
173. 1c assays in the monitoring of diabetes. Upsala J Med Sci 1993; 98: 335-8.
174. Little RR, England JD, Wiedmeyer H-M, McKenzie EM, Mitra R, Erhart PM, Durham JB, Goldstein DE. Intel-laboratory standardization of glycated hemoglobin determinations. Clin Chem 1986; 32: 358-60.